Fingerprint
Dive into the research topics of 'Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
Shlomo Elias*, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
13
Scopus
citations